TY - JOUR
T1 - PLASMA AND CEREBROSPINAL-FLUID PHARMACOKINETICS OF RECOMBINANT
INTERFERON ALPHA-A IN MONKEYS - COMPARISON OF INTRAVENOUS,
INTRAMUSCULAR, AND INTRAVENTRICULAR DELIVERY
AU - Collins, J
AU - Riccardi, Riccardo
AU - Trown, P
AU - Oneill, D
AU - Poplack, D.
PY - 1985
Y1 - 1985
N2 - Interferons are currently undergoing clinical testing in patients with cancer and other diseases. A variety of routes of administration are being utilized, and there is particular interest in delivery of interferon to the central nervous system. A biphasic decline in plasma concentrations was observed in monkeys following an i.v. bolus, with initial half-times of 15 to 33 min and terminal half-times of 1.7 to 4.6 hours. Total body clearance ranged from 24 to 39 ml/sq. m/min and steady-state volume of distribution was similar to extracellular space. CSF exposure was 1% or less than that of plasma. Intramuscular injections produced lower peak concentrations and more sustained levels, but there was substantial variation in bioavailability (range 19-103%). Levels in the CSF were not detectable for the i.m. route. For intraventricular doses, CSF exposure was 3,000-fold greater than for i.v. doses, despite a 20-fold lower dose
AB - Interferons are currently undergoing clinical testing in patients with cancer and other diseases. A variety of routes of administration are being utilized, and there is particular interest in delivery of interferon to the central nervous system. A biphasic decline in plasma concentrations was observed in monkeys following an i.v. bolus, with initial half-times of 15 to 33 min and terminal half-times of 1.7 to 4.6 hours. Total body clearance ranged from 24 to 39 ml/sq. m/min and steady-state volume of distribution was similar to extracellular space. CSF exposure was 1% or less than that of plasma. Intramuscular injections produced lower peak concentrations and more sustained levels, but there was substantial variation in bioavailability (range 19-103%). Levels in the CSF were not detectable for the i.m. route. For intraventricular doses, CSF exposure was 3,000-fold greater than for i.v. doses, despite a 20-fold lower dose
KW - interferon alpha-A
KW - interferon alpha-A
UR - https://publicatt.unicatt.it/handle/10807/16896
UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=0022402795&origin=inward
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0022402795&origin=inward
U2 - 10.1089/cdd.1985.2.247
DO - 10.1089/cdd.1985.2.247
M3 - Article
SN - 0732-9482
VL - 2
SP - 247
EP - 253
JO - Cancer Drug Delivery
JF - Cancer Drug Delivery
IS - 4
ER -